In Vivo Pharma Intelligence | The Growth Path for Drug Discovery Partners

Nov 2022

Originally published by In Vivo Pharma Intelligence on November 15, 2022

James West, Director in Lincoln’s Healthcare Group, explains the key trends and mergers and acquisitions (M&A) dynamics in the drug discovery industry.

View the original article.

Summary

Contributor

Related Perspectives

Lincoln’s Latest

In Q3 2020, Lincoln International introduced Lincoln’s Latest video series. Experts from across industries, services and geographies, share perspectives on current trends, recent observations and future outlooks through this video… Read More

Surging Medical Inflation Fuels Continued Interest in Self-Funding and Cost Containment

During the past 18 months, inflation has accelerated to levels not seen since the early 1980s. The cost of energy, food and other staples has increased rapidly and is expected… Read More

Lincoln International Expands Presence to Southeast, Opening Miami and Atlanta Offices

Continued growth spurs openings in new geographies for both client coverage and talent acquisition Lincoln International announced today that it has expanded its U.S. footprint with the opening of offices… Read More

Discovering the Investment Opportunity in Pre-Clinical CROs

The process to bring a drug to market is likely to be extensive and costly, from the starting points of research and development (R&D) across all phases of clinical trials… Read More